Abemaciclib mesylate is a small molecule, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) that has been approved for use in the treatment of certain types of breast cancer. It is marketed under the trade name Verzenio by Eli Lilly and Company. Abemaciclib mesylate has the chemical name (S)-4-(4-(((4-(ethylamino)-6-(4-(hydroxyethyl)-2-(methoxy)-3-morpholinopropoxy)pyrimidin-2-yl)amino)methyl)phenyl)oxazolidin-2-one mesylate, a molecular formula of C27H32N8O5.CH4O3S, formula weight of 593.67 g/mol and CAS No. 1231930-82-7.
Top 10 Keywords related to Abemaciclib mesylate from Google are:
Synonyms of Abemaciclib mesylate are: Abemaciclib monomesylate, LY-2835219 mesylate
Health Benefits of Abemaciclib mesylate: Abemaciclib mesylate is a selective inhibitor of CDK4/6, which are key regulators of cell cycle progression. By inhibiting CDK4/6, abemaciclib prevents the progression of the cell cycle from the G1 to the S phase, leading to the inhibition of cancer cell growth. Abemaciclib mesylate is used to treat certain types of breast cancer, including hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Potential Effects of Abemaciclib mesylate: Abemaciclib mesylate has been shown to be effective as a single agent or in combination with other chemotherapeutic agents in the treatment of certain types of breast cancer. It has been found to significantly improve progression-free survival and overall survival in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Abemaciclib mesylate has also been investigated for use in other types of cancer, including lung cancer, pancreatic cancer, and glioblastoma.
Product Mechanism of Action: Abemaciclib mesylate is a selective inhibitor of CDK4/6, which are key regulators of cell cycle progression. By inhibiting CDK4/6, abemaciclib prevents the progression of the cell cycle from the G1 to the S phase, leading to the inhibition of cancer cell growth. Abemaciclib also induces apoptosis, or programmed cell death, in cancer cells.
Safety: Abemaciclib mesylate is generally safe and well-tolerated in patients with breast cancer. The most common adverse reactions reported with the use of abemaciclib include diarrhea, fatigue, nausea, vomiting, decreased appetite, abdominal pain, neutropenia, infections, and thrombocytopenia. More serious adverse reactions include venous thromboembolism, interstitial lung disease, and hepatotoxicity.
Side Effects: The side effects of abemaciclib mesylate depend on the dose and duration of treatment. Common side effects include diarrhea, fatigue, nausea, vomiting, decreased appetite, abdominal pain, neutropenia, and thrombocytopenia. More serious adverse reactions include venous thromboembolism, interstitial lung disease, and hepatotoxicity. Patients receiving abemaciclib mesylate should be closely monitored for signs of infection, bleeding, or hepatotoxicity.
Dosing Information: The recommended dose of abemaciclib mesylate for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer is 150 mg twice daily. The dose may be adjusted based on the patient's age, weight, and overall health. Abemaciclib mesylate should be taken with food to reduce the risk of gastrointestinal adverse reactions.
Conclusion: Abemaciclib mesylate is a selective inhibitor of CDK4/6 that has been approved for use in the treatment of certain types of breast cancer. It inhibits cancer cell growth by preventing the progression of the cell cycle from the G1 to the S phase. Abemaciclib mesylate is generally safe and well-tolerated in patients with breast cancer, but serious adverse reactions may occur. The recommended dose and duration of treatment may vary depending on the patient's age, weight, and overall health. Patients receiving abemaciclib mesylate should be closely monitored for signs of infection, bleeding, or hepatotoxicity.
